A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Common bile duct (CBD) cancer is a relatively rare malignancy that arises from the biliary epithelium and is associated with a poor prognosis. Here, we report a case of advanced metastatic CBD cancer successfully treated by chemotherapy with gemcitabine combined with S-1(tegafur+gimeracil+oteracil). A 65-year-old male presented with pyogenic liver abscess. After antibiotic therapy and percutaneous drainage, follow-up computed tomography (CT) showed an enhanced nodule in the CBD. Biopsy was performed at the CBD via endoscopic retrograde cholangiopancreatography,which showed adenocarcinoma. Additional CT and magnetic resonance imaging showed multiple small nodules in the right hepatic lobe, which were confirmed as metastatic adenocarcinoma by sono-guided liver biopsy. The patient underwent combination chemotherapy with gemcitabine and S-1. After nine courses of chemotherapy, the hepatic lesion disappeared radiologically. Pylorus-preserving pancreaticoduodenectomy was performed, and no residual tumor was found in the resected specimen. Three weeks after the operation, the patient was discharged with no complications. Through 3 months of follow-up, no sign of recurrence was observed on CT scan. Gemcitabine combined with S-1 may be a highly effective treatment for advanced cholangiocarcinoma.
Abstract
Common bile duct (CBD) cancer is a relatively rare malignancy that arises from the biliary epithelium and is associated with a poor prognosis. Here, we report a case of advanced metastatic CBD cancer successfully treated by chemotherapy with gemcitabine combined with S-1(tegafur+gimeracil+oteracil). A 65-year-old male presented with pyogenic liver abscess. After antibiotic therapy and percutaneous drainage, follow-up computed tomography (CT) showed an enhanced nodule in the CBD. Biopsy was performed at the CBD via endoscopic retrograde cholangiopancreatography,which showed adenocarcinoma. Additional CT and magnetic resonance imaging showed multiple small nodules in the right hepatic lobe, which were confirmed as metastatic adenocarcinoma by sono-guided liver biopsy. The patient underwent combination chemotherapy with gemcitabine and S-1. After nine courses of chemotherapy, the hepatic lesion disappeared radiologically. Pylorus-preserving pancreaticoduodenectomy was performed, and no residual tumor was found in the resected specimen. Three weeks after the operation, the patient was discharged with no complications. Through 3 months of follow-up, no sign of recurrence was observed on CT scan. Gemcitabine combined with S-1 may be a highly effective treatment for advanced cholangiocarcinoma.
참고문헌 (20)
- Khan SA, "Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document", Gut, (51 Suppl 6), pp.VI1~VI9 (2002)
- Nakeeb A, "Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors", Ann Surg, 224, pp.463~473 (1996)
- de Groen PC, "Biliary tract cancers", N Engl J Med, 341, pp.1368~1378 (1999)
- Kubicka S, "Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas", Hepatogastroenterology, 48, pp.783~789 (2001)
- Jarnagin WR, "Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma", Ann Surg, 234, pp.507~517 (2001)
- Kondo S, "Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment", J Hepatobiliary Pancreat Surg, 15, pp.41~54 (2008)
- Farley DR, "“Natural history” of unFigresected cholangiocarcinoma: patient outcome after noncurative intervention", Mayo Clin Proc, 70, pp.425~429 (1995)
- Glimelius B, "Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer", Ann Oncol, 7, pp.593~600 (1996)
- Penz M, "Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer", Ann Oncol, 12, pp.183~186 (2001)
- Tsavaris N, "Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer", Invest New Drugs, 22, pp.193~198 (2004)
- Gebbia V, "Treatment of inoperable and", or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study, 2001, pp.19, 4089~4091
- Ueno H, "Phase II study of S-1 in patients with advanced biliary tract cancer", Br J Cancer, 91, pp.1769~1774 (2004)
- Yoshizawa J, "Experimental study of combination therapy with S-1 against pancreatic cancer", Cancer Chemother Pharmacol, 64, pp.1211~1219 (2009)
- Hezel AF, "Systemic therapy for biliary tract cancers", Oncologist, 13, pp.415~423 (2008)
- Sasaki T, "Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer", Cancer Chemother Pharmacol, 65, pp.1101~1107 (2010)
- Kanai M, "A multi-institution phase II study of gemcitabine", S-1 combination chemotherapy for patients with advanced biliary tract cancer, 2011, pp.67, 1429~1434
- Yoshida R, "A case of gallbladder cancer which completely responded to gemcitabine", Gan To Kagaku Ryoho, 37, pp.1771~1773 (2010)
- Nitta S, "Biliary tract carcinoma in elderly patients in whom gemcitabine chemotherapy induced complete remission: a report of two cases", Gan To Kagaku Ryoho, 34, pp.941~943 (2007)
- Matsuo R, "A case of stage IVA intrahepatic biliary tract cancer successfully treated with gemcitabine", Gan To Kagaku Ryoho, 33, pp.1501~1504 (2006)
- Nakayama A, "An effective case of gemcitabine therapy with post-operative peritoneal recurrence of intrahepatic cholangiocarcinoma", Gan To Kagaku Ryoho, 37, pp.1595~1598 (2010)